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Regulatory Dendritic Cells Protect Mice
from Murine Acute Graft-versus-Host
Disease and Leukemia Relapse
on the development of immunosuppressive agents and
the ex vivo removal of the unfractionated donor T cell
population from the marrow graft (Lu et al., 2001). Al-
though these strategies have reportedly reduced GVHD,
there has been a reciprocal increase in the rate of graft
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Kagoshima University rejection, more severe immunosuppression and lethal
infections, as well as severe side effects (Lu et al., 2001).8-35-1 Sakuragaoka, Kagoshima City
Kagoshima 890-8520 Furthermore, the risk of leukemia relapse could be in-
creased in turn possibly due to the lack of an anti-2 Department of Advanced Medical Science
The Institute of Medical Science leukemia effect of the allogeneic T cells infused, the so
called graft-versus-leukemia (GVL) effect (Tsukada etThe University of Tokyo
4-6-1 Shirokanedai, Minato-ku al., 1999).
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3 Department of Medicine gen (Ag)-presenting cells (APCs) to enhance T cell immu-
nity whereas normal immature DCs (iDCs) are involved inTeikyo University School of Medicine
2-11-1 Kaga, Itabashi-ku the induction of peripheral T cell tolerance under steady
state conditions (Banchereau et al., 2000; Hawiger etTokyo 173-8605
4 Division of Human Retroviruses al., 2001; Roncarolo et al., 2001). However, the clinical
application of normal iDCs may not be suitable for theCenter for Chronic Viral Diseases
School of Medicine treatment of immunopathogenic diseases, because they
likely change into mature under inflammatory conditionsKagoshima University
8-35-1 Sakuragaoka, Kagoshima City (Roncarolo et al., 2001). Therefore, further development
of DCs with a potent negative regulatory ability for TKagoshima 890-8520
Japan cells is thought to facilitate their use for treatment or
prevention of immunopathologic diseases. We have re-
cently established human and murine DCs with potent
immunoregulatory property (designated as regulatorySummary
DCs [rDCs]) to impair the functions of alloreactive/xeno-
reactive T cells (Sato et al., in press). In this study, weWe have established a novel immunotherapeutic ap-
proach involving dendritic cells (DCs) with potent im- examined the therapeutic effect of murine rDCs on acute
GVHD and leukemia relapse in allogeneic BMT in micemunoregulatory property (designated as regulatory
DCs [rDCs]) for acute graft-versus-host disease bearing leukemia.
(GVHD) and leukemia relapse in allogeneic bone mar-
row (BM) transplantation (BMT) in mice bearing leuke- Results
mia. rDCs displayed high levels of MHC molecules and
extremely low levels of costimulatory molecules. A rDCs Impair T Cell Function
single injection of rDCs following allogeneic BMT con- mDCs (H-2d) showed high expression levels and percent
trolled the ability of the transplanted T cells to induce positive cells for the DC marker (CD11c), costimulatory
acute GVHD and graft-versus-leukemia (GVL) effect in molecules (CD40, CD80, and CD86), and MHC mole-
the recipients bearing leukemia, and that resulted in cules (I-Kd and I-A/I-E) (Table 1; Figure 1A), and a potent
protection from the lethality caused by acute GVHD activation of allogeneic CD4 T cells (H-2b or H-2k) (Table
and tumor burden. Thus, the use of rDCs may be thera- 1; Figure 1B). In contrast, rDCs showed high expression
peutically useful for the treatment of acute GVHD and levels of the DC marker and MHC molecules with ex-
leukemia relapse in allogeneic BMT. tremely low levels of costimulatory molecules (Table 1;
Figure 1A). Furthermore, rDCs (H-2d) showed a lower
Introduction activation of allogeneic CD4 T cells (H-2b or H-2k) than
mDCs or 1,25 dihydroxyvitamin D3 (D3)-conditioned
Allogeneic bone marrow (BM) transplantation (BMT) is DCs known as tolerant DCs (Penna and Adorini, 2000;
an effective treatment of leukemia as well as genetic Griffin et al., 2001) (Table 1; Figure 1B). We also observed
disorders. However, its success is dependent on the similar phenotype and allogeneic T cell stimulatory ca-
prompt identification of a suitable donor and on the pacity of rDCs in other strains (H-2b or H-2q) (Table 1).
avoidance of opportunistic infections and severe graft- We examined the effect of rDCs (H-2d) on effector
versus-host disease (GVHD) (Sato et al., 1999; Shlom- functions of in vivo-primed allogeneic CD4 T cells
chik et al., 1999). GVHD is mainly due to activation of (H-2b), which were obtained from the spleen of recipients
alloreactive T cells in donor BM inoculum (Sato et al., (H-2d) of BM cells plus spleen mononuclear cells (BMS,
1999; Tsukada et al., 1999). Most therapeutic ap- H-2b) 5 days after transplantation. rDCs (H-2d) inhibited
proaches designed to reduce acute GVHD have focused mDC (H-2d)-induced activation of in vivo-primed
I-KbCD4T cells in a dose-dependent manner, whereas
the addition of mDCs (H-2d) into the coculture of in vivo-*Correspondence: katsuaki@m3.kufm.kagoshima-u.ac.jp
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primed I-KbCD4 T cells and mDCs (H-2d) slightly en-
hanced this response (Figure 1C). On the other hand,
the coculture with mDCs obtained from different strains
(H-2d and H-2q) additively enhanced the response of
these I-KbCD4 T cells whereas the addition of rDCs
(H-2q) had little or no effect on their response to mDCs
(H-2d), indicating that this rDC-mediated regulation is
Ag specific. Similar results were observed in other strain
combinations (Figure 1D; see supplemental data at http://
www.immunity.com/cgi/content/full/18/3/367/DC1).
We also examined the effect of rDCs (H-2d) on cyto-
toxic T lymphocyte (CTL) activity of in vivo-primed allo-
geneic CD8 T cells (H-2b) obtained from the recipients
(H-2d) of BMS (H-2b) as described above. In vivo-primed
I-KbCD8 T cells showed CTL activity against P815
cells (H-2d), but not EL4 cells (H-2b) and concanavalin A
(Con A) blasts (H-2q) (Figure 1E), indicating that their
cytotoxicity was H-2d specific. Furthermore, the cyto-
toxic activity of in vivo-primed I-KbCD8 T cells against
P815 cells was suppressed when cocultured with rDCs
(H-2d), whereas mDCs (H-2d) caused their further activa-
tion (Figure 1E; see supplemental data at http://www.
immunity.com/cgi/content/full/18/3/367/DC1). In addi-
tion, treatment with mDCs or rDCs obtained from synge-
neic (H-2b) and third party (H-2q) strains did not affect
their activity (Figure 1E). These results indicate that the
regulation of CTL activity by rDCs is Ag specific. Similar
results were observed in other strain combinations (Fig-
ure 1F).
We further examined the ability of rDCs to induce a
tolerance in allogeneic CD4 T cells (Figure 1G). Alloge-
neic CD4 T cells (H-2b) stimulated with mDCs (H-2d) in
a first coculture responded vigorously to restimulation
with mDCs (H-2d). In contrast, allogeneic CD4 T cells
(H-2b) primed with rDCs (H-2d) were hyporesponsive to
further stimulation with mDCs (H-2d). Furthermore, the
addition of interleukin (IL)-2 to a second culture partly
enhanced this response when rDCs were used as APCs
in the priming. On the other hand, CD4 T cells (H-2b)
primed with mDCs (H-2d) exhibited a similar response
to mDCs (H-2q or H-2k) in a second culture to that of
unprimed allogeneic CD4T cells (H-2b) with mDCs (H-2q
or H-2k) in the first coculture whereas CD4 T cells (H-2b)
primed with rDCs (H-2d) exhibited slightly lower re-
sponse to mDCs (H-2q or H-2k). We also observed similar
results in other strain combinations (Figure 1H). In addi-
tion, the degree of rDC-induced T cell hyporespon-
siveness was higher than that of D3-conditioned DCs
(Figure 1G; see supplemental data at http://www.
immunity.com/cgi/content/full/18/3/367/DC1). These
results indicate that rDCs are potent APCs to induce
tolerant T cells as well as to suppress the activation of
effector T cells.
rDCs Protected the Recipients of Allogeneic BMS
from the Lethality Caused by Acute GVHD
To clarify the therapeutic effect of rDCs on acute GVHD
in allogeneic BMT, we examined the effect of a single
injection of rDCs (H-2d) on the lethality caused by acute
GVHD in the recipients (H-2d) of BMS (H-2b). All recipients
of allogeneic BMS died on day 8 following transplanta-
tion (Figure 2A). In these mice, clinical symptoms of
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acute GVHD, such as hair ruffling, lower mobility, and
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Figure 1. rDCs Regulate the Function of T Cells
(A) Cells were stained with the stated mAbs, and cell surface expression was analyzed by flow cytometry. Data are represented by a dot plot.
(B) CD4 T cells (H-2b) were cultured with mDCs or rDCs (H-2d) at various T cell:DC ratios, and the proliferative response was measured.
(C and D) I-KbCD4 T cells or I-KdCD4 T cells obtained from the transplanted recipients (H-2d) (C) or (H-2q) (D) were cultured with mDCs
(H-2d) (C) or (H-2q) (D) in the presence or absence of mDCs or rDCs obtained from the indicated strains at various T cell:DC ratios, and the
proliferative response was measured. Primed CD4 T cells (H-2b) plus mDCs (H-2d) (C) or primed CD4 T cells (H-2d) plus mDCs (H-2q) (D)
versus any other group, P  0.01.
(E and F) I-KbCD8 T cells or I-KdCD8 T cells obtained from the transplanted recipients (H-2d) (E) or (H-2b) (F) were cultured with medium
alone (none) or the indicated types of DCs at a T cell/DC ratio of 10:1 and were subjected to CTL assay against the targeted cells obtained
from various strains. CD8 T cells alone versus any other group, P  0.01.
(G and H) CD4 T cells (H-2b) (G) or (H-2d) (H) were cultured with or without the indicated types of DCs (H-2d) (G) or (H-2q) (H) at a T cell/DC
ratio of 10:1 in a first coculture. In another experiment, CD4 T cells obtained from a first coculture were then cultured with medium alone
(none) or mDCs obtained from various strains at a T cell/DC ratio of 10:1 in the presence or absence of IL-2 in a second coculture, and the
proliferative response was measured. Primed CD4 T cells (H-2b) plus mDCs (G) or primed CD4 T cells (H-2d) plus mDCs (H) versus any other
group, P  0.01. Five replicate experiments with similar results were pooled.
weight loss, became apparent within 6 days. On the therapeutic effect of rDCs on acute GVHD was stronger
than that of D3-conditioned DCs (P  0.01, Figure 2B).other hand, a single injection of mDCs (1.5 106/mouse,
H-2d) 2 days following transplantation enhanced the le- We also observed similar specific efficacy of rDCs in
other strain combinations (Figure 2C).thality caused by acute GVHD (P  0.01, Figure 2A). In
contrast, a single injection with the host-matched rDCs We evaluated the therapeutic efficacy of rDCs (H-2d)
in the recipients (H-2d) of BMS (H-2b) (Figure 2D). The(1.5 106/mouse, H-2d), but not host-mismatched rDCs
(H-2b and H-2q), 2 days following transplantation com- therapeutic effect of rDCs on acute GVHD was observed
in a dose-dependent fashion (1.5  104–1.5  106/pletely protected the recipients from this lethality, and
they survived over 60 days with little or no signs of acute mouse) when the recipients received a single injection
with rDCs 2 days after transplantation, and the repetitiveGVHD (P  0.01, Figures 2A and 2B). In addition, the
Immunity
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Figure 2. rDCs Protected the Recipients of Allogeneic BMS from the Lethality Caused by Acute GVHD
(A and B) Recipients (H-2d) of BM cells or BMS (H-2b) were injected with or without the indicated types of DCs 2 days after transplantation.
(C) Recipients (H-2b) of BMS (H-2q) were injected with or without the indicated types of DCs 2 days after transplantation. (D) Recipients (H-2d)
of BMS (H-2b) were injected with or without various doses of rDCs (H-2d) on the indicated days after transplantation. (E and F) Recipients
(H-2d) of BMS (H-2b) injected with rDCs (H-2d) were treated with the indicated Abs (E) or injected with the indicated types of CD4CD25 T
cells (H-2b) (F) after transplantation as described in Experimental Procedures. Untreated recipients of allogeneic BMS versus any other group,
P  0.01. Two replicate experiments with similar results were pooled.
injections of rDCs (1.5  104 and 1.5  105/mouse) 2 Analysis of the Regulatory Effect of rDCs
in the Recipients of Allogeneic BMSand 5 days after transplantation enhanced the survival
rate in the recipients (P  0.01). On the other hand, a We examined the I-Kb donor-derived T cells in spleen
mononuclear cells in the recipients (H-2d) of BMS (H-2b)single injection with rDCs (1.5 106/mouse) 5 days after
transplantation reduced the therapeutic effect whereas 5 days after transplantation (Figure 3A). I-KbCD3,
I-KbCD4, and I-KbCD8 subpopulations were greatera high-dose injection (5  106/mouse) with rDCs com-
pletely protected the recipients from the lethality. in the recipients injected with mDCs following trans-
Immunotherapy with Dendritic Cells
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Figure 3. rDCs Impair Allogeneic Ag-Specific Responses of CD4 T Cells and CD8 T Cells in Transplanted Mice
Recipients (H-2d) of BMS (H-2b) were injected with or without mDCs or rDCs (H-2d), and spleen mononuclear cells and sera were obtained
from each group 5 days after transplantation. (A) Cells were stained with the stated mAbs, and cell surface expression was analyzed by flow
cytometry. Data are expressed as percent positive cells. (B) I-KbCD4 T cells obtained from spleen mononuclear cells were cultured with
medium alone (none) or mDCs (H-2d or H-2q) in the presence or absence of IL-2 at a T cell/DC ratio of 10:1, and the proliferative response
was measured. (C) I-KbCD8 T cells obtained from spleen mononuclear cells were subjected to CTL assay against P815 cells or EL4 cells.
(D) Concentrations of IFN-, TNF-, and IL-12p40 in sera were evaluated by ELISA. Untreated recipients of allogeneic BMS versus any other
group, P  0.01. (E) Recipients (H-2d) of BMS (H-2b) were injected with CFSE-labeled rDCs (H-2d) 2 days after transplantation, and CFSE-
labeled rDCs in spleen mononuclear cells were determined at the indicated days after injection by flow cytometry. Five replicate experiments
with similar results were pooled.
plantation (mDC-treated recipients) than untreated re- response, and the response of these I-KbCD4 T cells
to mDCs (H-2q) was slightly lower than those of othercipients of allogeneic BMS (untreated recipients). On the
other hand, I-KbCD3 and I-KbCD8 subpopulations groups of recipient mice.
To examine CTL activity of I-KbCD8 T cells to recipi-were decreased in the recipients injected with rDCs fol-
lowing transplantation (rDC-treated recipients) as com- ent tissues (H-2d), we examined the lytic activity of
I-KbCD8 T cells obtained from the recipients againstpared with untreated recipients, although there were no
significant differences among I-KbCD4 subpopula- P815 cells and EL4 cells (Figure 3C). I-KbCD8 T cells
obtained from mDC-treated recipients showed a highertions.
We also examined the allogeneic response of lytic activity against P815 cells than those obtained from
untreated recipients. In contrast, I-KbCD8 T cells ob-I-KbCD4T cells to mDCs (Figure 3B). I-KbCD4T cells
obtained from untreated recipients and mDC-treated tained from rDC-treated recipients exhibited a reduced
lytic activity against P815 cells. We also observed littlerecipients responded vigorously to mDCs (H-2d). In con-
trast, I-KbCD4 T cells obtained from rDC-treated re- or no cytotoxic activity of these I-KbCD8 T cells
against EL4 cells, indicating that their cytotoxicity wascipients were hyporesponsive to mDCs (H-2d). Further-
more, the addition of IL-2 to cultures partly restored this H-2d specific.
Immunity
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Figure 4. Characterization of Donor-Derived CD4CD25 T Cells in Transplanted Mice
Allogeneic transplantation was performed as described in Figure 3, and I-KbCD4 T cells were obtained from spleen mononuclear cells in
each group.
(A and B) I-KbCD4 T cells were assayed for phenotype (A) and cytokine profile (B) by flow cytometry. Data are expressed as percent positive
cells. CD4 T cells obtained from normal mice versus any other group, P  0.01.
(C) CD4CD25 T cells isolated from normal mice (H-2b) or I-KbCD4CD25 T cells isolated from I-KbCD4 T cells in each group of recipients
were assayed for phenotype by flow cytometry. Data are represented by a dot plot.
(D) Unprimed CD4CD25 T cells (H-2b) or I-KbCD4 CD25 T cells isolated from rDC-treated recipients on the indicated days after transplanta-
tion were assayed for CD152 expression by flow cytometry. Data are expressed as percent positive cells. Unprimed CD4CD25 T cells
versus any other group, P  0.01.
(E) CD4 T cells (H-2b), unprimed CD4CD25 T cells (H-2b), and/or I-KbCD4CD25CD152 T cells were cultured with or without mDCs or
rDCs (H-2d or H-2q) at a T cell/DC ratio of 10:1, and the proliferative response was measured.
(F) CD4 T cells (H-2b) were cultured with mDCs (H-2d) at a T cell/DC ratio of 10:1 in the presence or absence of the different numbers of
unprimed CD4CD25 T cells or I-KbCD4CD25CD152 T cells isolated from rDC-treated recipients on day 5 after transplantation, and the
proliferative response was measured.
(G) CD4 T cells (H-2b) were cultured with mDCs (H-2d) in the presence or absence of unprimed CD4CD25 T cells or I-KbCD4CD25 T
cells isolated from rDC-treated recipients on the indicated days after transplantation at a T cell/CD25T cell/DC ratio of 10:1:1, and the
proliferative response was measured.
(H) CD4 T cells (H-2b) were cultured with or without mDCs (H-2d) in the presence or absence of I-KbCD4CD25 CD154 T cells,
I-KbCD4CD25CD152 T cells, or IL-2 at a T cell/CD25T cell/DC ratio of 10:10:1. For Transwell experiments, I-KbCD4CD25CD152 T
cells plus mDCs (H-2d) were either added directly to the coculture of CD4 T cells (H-2b) with mDCs (H-2d) or were separated in 24-well plates.
Following depletion of mDCs, T cells were transferred to 96-well plates to measure the proliferative response. CD4 T cells plus mDCs (E, G,
H) or CD4 T cells, unprimed CD4CD25 T cells plus mDCs (G) versus any other group, P  0.01. Five replicate experiments with similar
results were pooled.
We further evaluated the levels of proinflammatory and the half-life of the injected rDCs was around 18
days after transplantation.cytokines in serum in the recipients of allogeneic BMS
5 days after transplantation (Figure 3D). The levels of To examine the stability of rDCs under inflammatory
conditions after in vivo infusion, we examined the phe-interferon (IFN)-, tumor necrosis factor (TNF)-, and IL-
12p40 in serum obtained from mDC-treated recipients notype and allogeneic T cell stimulatory capacity of
rDCs obtained from rDC (H-2d)-treated recipients (H-2b)were higher than those in untreated recipients, whereas
the production of these proinflammatory cytokines was of BMS (H-2q) 5 days after transplantation (Table 1). We
observed little or no change in the property of rDCssignificantly reduced in rDC-treated recipients (Figure 3D).
To better understand the half-life of the injected rDCs, following in vivo infusion. These results indicate that
rDCs retain their property even under inflammatory con-the recipients (H-2d) of BMS (H-2b) were injected with
carboxyfluorescein diacetate-succinimidyl ester (CFSE)- ditions in vivo.
labeled rDCs (H-2d), and their trafficking in spleen was
examined by flow cytometry (Figure 3E). We detected Analysis of CD4CD25 T Cells in the Protected Mice
CD4CD25 regulatory T (Tr) cells, which suppress theapproximately 4% of CFSE-labeled rDCs in spleen
mononuclear cells the next day after transplantation, function of CD4 T cells, are supposed to maintain im-
Immunotherapy with Dendritic Cells
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Figure 5. Involvement of cAMP and p27kip1 in an Induction of Allogeneic Ag-Specific Tolerant CD4 T Cells by rDCs
(A, C, and D) CD4 T cells (H-2b) were obtained from the coculture of CD4 T cells (H-2b) with the indicated types of DCs (H-2d) or I-KbCD4
CD25CD152 Tr cells as described in Figure 4 at a T cell/DC ratio of 10:1 or at a T cell/CD25 T cell ratio of 1:1. (B and E) Allogeneic
transplantation was performed as described in Figure 3, and I-KbCD4 T cells obtained from spleen mononuclear cells in each group were
then cultured with mDCs (H-2d or H-2q) at a T cell/DC ratio of 10:1. Following these procedures, CD4 T cells were isolated from the coculture.
(A and B) The concentration of intracellular cAMP was measured. (C, D, and E) The expression of p27kip1 was analyzed by immunoblot. Five
replicate experiments with similar results were pooled.
munologic self-tolerance or control immunopathogenic Similar to the previous report (Takahashi et al., 2000), a
part of CD4CD25 T cells obtained from normal micediseases (Thornton and Shevach, 1998; Sakaguchi,
2000; Maloy and Powrie, 2001). We therefore examined (unprimed CD4CD25 T cells, H-2b) constitutively ex-
pressed CD152, whereas they did not express CD154the subpopulations of transplanted I-KbCD4 T cells
and their ability to produce cytokines in mDC- or rDC (Figure 4C; see supplemental data at http://www.
immunity.com/cgi/content/full/18/3/367/DC1). On the(H-2d)-treated recipients (H-2d) of BMS (H-2b). CD25 and
CD154 subpopulations were increased in I-KbCD4 other hand, CD4CD25 T cells obtained from mDC-
treated recipients predominantly expressed CD154,T cells obtained from untreated recipients and mDC-
treated recipients whereas CD25 and CD152 subpop- whereas a large proportion of CD4CD25 T cells ob-
tained from rDC-treated recipients expressed CD152ulations were increased in I-KbCD4 T cells obtained
from rDC-treated recipients as compared with CD4 T (Figure 4C; see supplemental data at http://www.
immunity.com/cgi/content/full/18/3/367/DC1). In addi-cells obtained from normal mice (unprimed CD4T cells,
H-2b) (Figure 4A). On the other hand, IFN-- and IL-2- tion, the expression level of CD152 was increased in
CD4CD25 T cells after the injection of rDCs in theproducing cells were increased in I-KbCD4 T cells
obtained from untreated recipients and mDC-treated recipients of allogeneic BMS, and they retained their
expression level until 60 days after transplantation (Fig-recipients, whereas IL-10-producing cells were in-
creased in I-KbCD4 T cells obtained from rDC-treated ure 4D; see supplemental data at http://www.immunity.
com/cgi/content/full/18/3/367/DC1).recipients as compared with unprimed CD4 T cells
(H-2b) (Figure 4B). We also examined the functional difference of
I-KbCD4CD25 T cells obtained from mDC- or rDC-We examined the phenotype of I-KbCD4CD25 T
cells obtained from mDC- or rDC-treated recipients. treated recipients (referred to hereafter as CD4CD25
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CD154 T cells or CD4CD25CD152 T cells, respec- CD4T cells (H-2b) in vitro. We observed similar amounts
of cAMP and expression levels of p27kip1 between un-tively). Unprimed CD4CD25 T cells (H-2b) or CD4
CD25CD152 T cells not only showed poor response stimulated CD4 T cells and CD4CD25CD152 Tr
cells, which were obtained from rDC (H-2d)-treated re-to mDCs and rDCs (H-2d or H-2q) but also inhibited the
proliferation of CD4 T cells (H-2b) in response to mDCs cipients (H-2d) of BMS (H-2b) 5 days after transplantation,
and these Tr cells did not affect them in CD4 T cells(H-2d or H-2q) (Figures 4E), indicating that their suppres-
sion is an Ag nonspecific. Furthermore, CD4CD25 following coculture (Figures 5A and 5D).
We also tested the involvement of cAMP and p27kip1CD152 T cells showed a more potent suppression than
unprimed CD4CD25 T cells (Figures 4E and 4F). In in the induction of Ag-specific tolerant CD4 T cells in
rDC (H-2d)-treated recipients (H-2d) of BMS (H-2b) (Fig-addition, the suppressive activity was upregulated in
CD4CD25 T cells after the injection of rDCs in the ures 5B and 5E). I-KbCD4 T cells obtained from mDC
(H-2d)-treated recipients 5 days after transplantationrecipients of allogeneic BMS, and they retained their
activity until 60 days after transplantation (Figure 4G). On showed decreased amounts of cAMP and expression
levels of p27kip1 following in vitro stimulation with mDCsthe other hand, the separation of CD4CD25CD152 T
cells virtually abolished this inhibitory effect, and the (H-2d and H-2q). In contrast, I-KbCD4 T cells obtained
from rDC-treated recipients 5 days after transplantationaddition of IL-2 restored the response of activated CD4
T cells at least partially (Figure 4H). We also observed showed constitutive high amounts of cAMP and expres-
sion levels of p27kip1. Furthermore, in vitro stimulationthat CD4CD25 CD154 T cells showed a vigorous
response to mDCs (H-2d), and the addition of CD4 of these CD4 T cells with mDCs (H-2d) enhanced the
amount of cAMP and the expression level of p27kip1CD25CD154 T cells did not affect the response of
CD4 T cells (H-2b) to mDCs (H-2d) (Figure 4H). These whereas the amount of cAMP and the expression level
of p27kip1 were significantly decreased following in vitroresults indicate that CD4CD25CD152 T cells as well
as unprimed CD4CD25 T cells act as Tr cells. stimulation with mDCs (H-2q).
We further examined the role of IL-10-producing CD4
T cells and CD4CD25 CD152 Tr cells in the thera- GVL Effect in rDC-Treated Leukemia-Bearing
Recipients of Allogeneic BMSpeutic effect of rDCs on acute GVHD. In vivo blockade
experiments showed that treatment with anti-CD25 mono- The current preclinical approach failed to control the
balance between anti-GVHD effect and GVL effect. Weclonal antibody (mAb) or anti-IL-10 Ab, but not anti-
TGF- mAb and control IgG (control Ig), significantly therefore examined the effect of rDCs (H-2d) on GVL
effect in leukemia (H-2d)-bearing recipients (H-2d) of BMSabrogated the therapeutic effect of rDCs on acute GVHD
(P 0.01), and the treatments with both anti-CD25 mAb (H-2b). All leukemia-bearing mice that received total
body irradiation (TBI) died 12 days after transplantationand anti-IL-10 Ab showed a more potent suppression
(Figure 2E). (Figures 6A and 6B) with marked hepatosplenomegaly
(Figure 6C), indicating that these recipients exhibited aWe also tested the effect of a single injection of un-
primed CD4CD25 Tr cells, CD4CD25CD154 T poor GVL effect. On the other hand, leukemia-bearing
recipients of allogeneic BM cells (approximately 4% ofcells, or CD4CD25CD152 Tr cells (each H-2b) follow-
ing transplantation on acute GVHD-induced lethality. CD8 T cells in the BM graft) survived until 30 days after
transplantation (P  0.01, Figures 6A and 6B), and theyCD4CD25CD152 Tr cells showed a more potent pro-
tective effect than unprimed CD4CD25 Tr cells died probably due to the leukemia, because they mani-
fested massive hepatosplenomegaly (Figure 6C). In con-whereas CD4CD25CD154 T cells enhanced the le-
thality (P  0.01, Figure 2F). trast, rDC-treated leukemia-bearing recipients of alloge-
neic BMS survived over 60 days (P  0.01, Figures 6A
and 6B), and they did not show apparent acute GVHDInvolvement of cAMP and p27kip1 in an Induction of
Allogeneic Ag-Specific Tolerant CD4 T Cells by rDCs and hepatosplenomegaly (P 0.01, Figure 6C), whereas
leukemia-bearing recipients of allogeneic BMS died 8The accumulation of cyclic AMP (cAMP) leads to the
upregulation of p27kip1 cyclin-dependent kinase (CDK) days after transplantation due to acute GVHD (Figures
6A and 6B). These results indicate that rDC-treated re-inhibitor, and these molecular events play a crucial role
in in vitro induction of tolerant CD4 T cells (Boussiotis cipients of allogeneic BMS showed an undetectable se-
verity of acute GVHD but retained a strong GVL effect.et al., 2000). We therefore examined the role of cAMP
and p27kip1 in in vitro induction of Ag-specific tolerant
CD4 T cells by allogeneic rDCs (Figures 5A and 5C). Discussion
CD4 T cells (H-2b) stimulated with rDCs (H-2d) had in-
creased amounts of cAMP and expression levels of In this study, we established a novel immunotherapeutic
approach involving rDCs to prevent acute GVHD andp27kip1 whereas CD4 T cells (H-2b) stimulated with
mDCs (H-2d) had decreased amounts of cAMP and ex- leukemia relapse in allogeneic BMT in mice bearing leu-
kemia mediated through the control of the ability of thepression levels of p27kip1 compared to unstimulated
Figure 6. GVL Effect in rDC-Treated Leukemia-Bearing Recipients of Allogeneic BMS
Leukemia (H-2d)-bearing recipients (H-2d) received BM (H-2b), BMS (H-2b), and/or rDCs (H-2d) as described in Experimental Procedures. (A and
B) Recipients were monitored for survival (A) and body weight (B). (C) Liver and spleen were obtained from representative recipients at the
time of death or 60 days after transplantation to determine their weight. Recipients that received TBI plus the inoculation with P815 cells
versus any other group, P  0.01. Two replicate experiments with similar results were pooled.
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transplanted T cells to induce acute GVHD and GVL (Penna and Adorini, 2000) has been extensively per-
formed in humans, the information about in vivo efficacyeffect.
In order to exploit Ag-specific immnunotherapy for of tolerant DCs as therapeutic agents for immunopatho-
genic diseases is limited in humans and animals. Thisacute GVHD and leukemia relapse, we successfully gen-
erated rDCs from the culture of BM cells with granulo- paper reports that tolerant DCs showed a prominent
therapeutic effect on immunopathogenic disease incyte-macrophage colony-stimulating factor (GM-CSF),
IL-10, transforming growth factor (TGF)-1, and lipo- which the treatment began even after disease progres-
sion. A dose response and timing analysis suggestspolysaccharide (LPS) as therapeutic agents in mice. Fur-
thermore, rDCs retained their T cell regulatory property that the increasing doses of rDCs and their sequential
infusions enhance their therapeutic efficacy on murinein vitro and in vivo even under inflammatory conditions.
However, the use of LPS is unlikely to be suitable for acute GVHD. On the other hand, the results obtained
from various strain combinations in allogeneic BMT sug-preparation of these cells in a clinical setting. On the
other hand, TNF- as well as LPS could generate rDCs gest that in vivo efficacy of rDC is closely associated
with the compatibility of MHC haplotypes between hostfrom the culture of BM cells with GM-CSF, IL-10, and
TGF-1 (data not shown). In addition, we have recently and rDCs. Interestingly, host APCs reportedly play a
crucial role in the initiation and the progression of acutereported that human modified DCs obtained from the
culture of monocytes with GM-CSF, IL-4, IL-10, TGF- GVHD, and their inactivation leads to the prevention of
acute GVHD (Shlomchik et al., 1999). We showed that1, and TNF- also act as rDCs to cause a potent immu-
noregulation in vitro (Sato et al., in press). Therefore, the the infused rDCs were still found in spleen in syngeneic
recipients for	18 days after allogeneic transplantation.strategy involving the use of rDCs is potentially useful for
the establishment of therapeutic approach in a clinical Thus, a long-term existence of host MHC-matched rDCs
might be crucial for their therapeutic efficacy.setting.
Analysis of phenotype and function of mDCs suggests We showed that rDCs directly suppressed not only
the effecor functions of in vivo-primed allogeneic CD4that they could efficiently deliver signal to T cell receptor
for Ag (TCR) ligands (signal 1) plus signal to costimula- and CD8 T cells but also their responsiveness to the
restimulation in vitro. Analysis of rDC-treated recipientstory molecules (signal 2) (Viola and Lanzavecchia, 1996),
resulting in the potent activation of T cells. Furthermore, revealed that they showed the impaired allogeneic Ag-
specific responses of the transplanted T cells as well asrepetitive stimulations with mDCs may cause clonal
expansion of alloreactive T cells resulting in the appear- the reduced productions of proinflammatory cytokines.
Thus, the mechanism responsible for the therapeuticance of their further allogeneic response. Conversely,
rDCs exhibited high levels of MHC molecules plus poor effect on acute GVHD involves the induction of tolerant
T cells as well as direct suppression on effector T cellsexpressions of costimulatory molecules, whereas D3-
conditioned DCs showed moderate expression levels in vivo.
Donor-type CD4CD25 Tr cells reportedly sup-of these molecules. In addition, rDCs showed lower acti-
vation of allogeneic T cells in the priming and more pressed acute GVHD-induced lethality in mice, and this
suppressive effect was partly mediated through IL-10potent induction of their tolerance upon restimulation
with mDCs than D3-conditioned DCs. These phenomena (Hoffmann et al., 2002; Taylor et al., 2002). On the other
hand, the suppressor function of CD4CD25 Tr cellsimply that the condition responsible for the induction of
T cell tolerance by tolerant DCs is that the degree of T reportedly could occur independently of TGF-1 (Piccirillo
et al., 2002). We showed that IL-10-producing CD4 Tcell activation in the priming is much lower than that on
restimulation. cells and CD4CD25CD152 Tr cells were increased
in rDC-treated recipients. The deletion of CD25 cellsPrevious study has shown that fibroblasts transfected
with HLA-DR7 alone (t-DR7) induced anergy in CD4 T as well as the neutralization of IL-10, but not TGF-1,
significantly impaired the therapeutic effect of rDCs oncell clones specific for HLA-DR7, whereas fibroblasts
transfected with HLA-DR7 and B7-1 (t-DR7/B7-1) in- acute GVHD, and their combination enhanced the sup-
pressive effect. Furthermore, CD4CD25CD152 Trduced productive stimulation (Boussiotis et al., 2000).
Therefore, the characteristic expression profile of MHC cells showed a more potent protective effect on acute
GVHD than unprimed CD4CD25 Tr cells. Thus, ourand costimulatory molecules in rDCs is associated with
their potent tolerance-inducing ability, in which they may results suggest that IL-10-producing CD4 T cells and
CD4CD25CD152 Tr cells play a redundant role indeliver potent signal 1 plus poor signal 2 to alloreactive
CD4 T cells. protection, and they are crucial for the therapeutic effect
of rDCs on acute GVHD mediated through the inhibitionA single injection of mDCs enhanced the lethality
caused by acute GVHD in the recipients of allogeneic on the transplanted alloreactive T cells.
A single injection of mDCs or rDCs increasedBMS. In addition, these recipients exhibited the in-
creased proportions and allogeneic responses of the CD4CD25CD154 T cells or CD4CD25CD152 Tr
cells in spleen by approximately 5-fold, respectively.transplanted T cells as well as the enhanced productions
of proinflammatory cytokines. The results suggest that Thus, antigenic stimulation of unprimed CD4 T cells
with allogeneic DCs may be necessary for the enhance-the injected mDCs activate the transplanted alloreactive
T cells via delivery of potent signal 1 plus signal 2 re- ment of these CD4CD25 T cells. Allogeneic mDCs
reportedly induced CD4CD25CD154 T cells from na-sulting in the enhancement of the lethality caused by
acute GVHD. ive CD4 T cells via the delivery of potent signal 1 plus
signal 2 (Banchereau et al., 2000; Jonuleit et al., 2000).Although in vitro analysis of tolerant DCs such as iDCs
(Jonuleit et al., 2000), IL-10-treated DCs (Steinbrink et These phenomena imply that signal 1 plus additional
signal(s) may be needed for the enhancement ofal., 1997; Sato et al., 2002), and D3-conditioned DCs
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Experimental ProceduresCD4CD25CD152 Tr cells by allogeneic rDCs. Al-
though the precise mechanism remains unknown, sev-
Cell Preparationeral possibilities may account for this regulation. We
mDCs were prepared by culturing BM cells obtained from female
observed that 7%–10% of CD4T cells in BMS inoculum BALB/c mice (H-2d), C57/BL6 mice (H-2b), DBA/1 mice (H-2q), or
were CD4CD25 T cells (data not shown). It is possible CBA/J mice (H-2k) (all from Charles River Laboratories, Raleigh, NC)
that these cells may preferentially survive in rDC-treated with murine GM-CSF (20 ng/ml; Pepro Tech., London, England) for
6 days followed by LPS (1 
g/ml, Sigma, St. Louis, MO) for 2 days.recipients of allogeneic BMS. Thus, rDCs may provide
rDCs were also generated from BM cells (H-2d, H-2b, or H-2q) culturedan environment promoting the naturally existing
with murine GM-CSF (20 ng/ml), murine IL-10 (20 ng/ml, PeproCD4CD25 Tr cell-mediated infectious tolerance (Ma-
Tech.), and human TGF-1 (20 ng/ml, Pepro Tech.) for 6 days fol-
loy and Powrie, 2001; Waldmann and Cobbold, 2001). lowed by LPS (1 
g/ml) for 2 days. D3-conditioned DCs were pre-
Further study will be needed to test this possibility. On pared from the culture of BM cells with GM-CSF (20 ng/ml) plus D3
the other hand, the mechanism underlying the genera- (10 nM, Sigma) for 6 days followed by LPS (1 
g/ml) for 2 days as
described previously (Griffin et al., 2001). T cells were negativelytion of CD4CD25 Tr cells from their precursor cells,
selected from spleen mononuclear cells obtained from normal miceincluding CD4CD25 T cells, has been debated (Maloy
(H-2d, H-2b, or H-2k) with mAbs to Ly-76, B220, Ly-6G, and I-A/I-Eand Powrie, 2001; Shevach, 2001). It is possible that
(all from BD PharMingen, San Diego, CA) plus sheep anti-rat IgGallogeneic rDCs can directly convert alloreactive
mAb-conjugated immunomagnetic beads (Dynal, Oslo, Norway).
CD4CD25– T cells into CD4CD25CD152 Tr cells me- Subsequently, CD4 T cells or CD8 T cells were negatively selected
diated through the interaction between unknown sur- from T cells with anti-CD8 mAb or anti-CD4 mAb (both from BD
face-bound molecule(s) on rDCs and receptor(s) on PharMingen) in combination with sheep anti-rat IgG mAb-conju-
gated immunomagnetic beads. These T cell preparations were typi-CD4CD25 T cells because CD4CD25CD152 Tr
cally 	97% pure as indicated by FACS analysis (Becton Dickinson,cells as well as unprimed CD4CD25 Tr cells showed
Mountain View, CA).a poor proliferative response to mDCs and rDCs. To test
this possibility, we are conducting experiments to detect
In Vitro Priming of T Cell Subsetsthe molecules specifically expressed on rDCs.
T cell subsets (107 ) were cultured in medium alone or primed with
It has been reported that stimulation with t-DR7 in- allogeneic mDCs, rDCs, or D3-conditioned DCs (106 ) at a T cell/DC
duced increased intracellular cAMP followed by the ratio of 10:1 for 3 days. After incubation, in vitro primed T cell subsets
upregulation of p27kip1 in DR7-specific CD4 T cell were negatively selected with DC-matched anti-I-K mAb (BD Phar-
Mingen) plus goat anti-mouse IgG mAb-conjugated immunomag-clones, and these molecular events arrested at the early
netic beads for their depletion. We collected viable T cell subsetsG1 phase of cell cycle, resulting in the inhibition of their
(1.5–2  107, 7–8  106, or 8–9  106 ) from the coculture withclonal expansion and the induction of their anergic state
allogeneic mDCs, rDCs, or D3-conditioned DCs, respectively. These(Boussiotis et al., 2000). We showed that in vivo and in preparations typically contained 0.1% of allogeneic DCs (CD11c
vitro stimulation with rDCs increased the amount of and allogeneic I-K cells) as indicated by FACS analysis. In vitro
cAMP and the expression level of p27kip1 in allogeneic primed T cell subsets were rested in medium containing murine
IL-2 (10 U/ml, Pepro Tech.) for 3 days and used for subsequentCD4 T cells in an Ag-specific manner whereas
experiments.CD4CD25CD152 Tr cells failed to induce these
events. Therefore, rDCs may specifically activate signal-
Models for Acute GVHD and Leukemia Relapseing events involving cAMP and p27kip1 in alloreactive
Recipients (H-2d or H-2b, five animals in each group) received lethalCD4 T cells mediated through the delivery of potent
TBI (10 Gy from a 60Co source, MBR-1505R2, Hitachi Medical, Tokyo,
signal 1 plus poor signal 2, and that result in the induc- Japan). Alternatively, recipients (H-2d, five animals in each group)
tion and maintenance of their tolerance as well as sup- were inoculated intravenously (i.v.) with P815 cells (2  105/0.2 ml,
pression of their clonal expansion via the blockade of H-2d; RIKEN Cell Bank, Tsukuba, Japan) 2 days before TBI to evalu-
ate the GVL effect (Tsukada et al., 1999). Allogeneic transplantationcell cycle progression.
was performed by a single injection of 0.2 ml of PBS containingTransplanted CD8 T cells reportedly participated in
host-mismatched nucleated BM cells (1.5  107/mouse) alone ora GVL effect possibly mediated through the perforin
0.4 ml of PBS containing host-mismatched BM cells (1.5  107/pathway (Tsukada et al., 1999). Our results suggest that
mouse) plus spleen mononuclear cells (1.5 107/mouse) into recipi-
allogeneic rDCs induced a more potent tolerance in ents through the tail vein. The day of transplantation was designated
CD4 T cells than in CD8 T cells. On the other hand, as day 0. Subsequently, recipients received a single or repetitive
leukemia-bearing recipients of allogeneic BM cells ex- i.v. injection(s) of host-matched or mismatched mDCs, rDCs, or D3-
conditioned DCs (1.5  104–5  106/0.2 ml/mouse) 2 and/or 5 dayshibited slight GVL effect although they survived without
after transplantation. Recipients were monitored once every daysymptoms of acute GVHD until 30 days after transplanta-
from the day of transplantation until they succumbed naturally totion. We hypothesized that allogeneic rDC-regulated cy-
GVHD and/or tumor burden or 60 days after transplantation to deter-totoxic activity in transplanted CD8 T cells, which fail
mine survival time and body weight. In another experiment, recipi-
to cause acute GVHD, may be sufficient to cause an ents were killed on the indicated days after transplantation to obtain
efficient GVL effect. serum and spleen. Alternatively, liver and spleen were obtained from
Collectively, the immunotherapeutic strategy using representative mice bearing leukemia at the time of death or 60
days after transplantation to determine their weight.rDCs provides benefits including prominent anti-GVHD
effect and GVL effect as well as undetectable side ef-
In Vivo Blockade Experimentsfects for the treatment of acute GVHD and leukemia
Recipients (H-2d) of BMS (3  107/mouse, H-2b) were injected withrelapse in murine allogeneic BMT. To establish a clini-
rDCs (1.5  106/mouse, H-2d) 2 days after transplantation. The i.v.cally useful strategy with rDCs for other immunopatho-
injections of anti-CD25 mAb (clone PC61, BD PharMingen), neu-
logic diseases including autoimmune diseases and allo- tralizing anti-IL-10 polyclonal Ab (model AB-417-NA, R&D System,
geneic/xenogeneic graft rejection, preclinical studies Minneapolis, MN), neutralizing anti-TGF- mAb (clone 1D11, R&D
with rDCs in animal immunopathogenic models are be- System), or preimmune rat IgG used as control Ig (each 500 
g/
mouse) were performed on days 3, 5, 7, 9, 10, 13, and 15 aftering conducted in our laboratories.
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transplantation. Treatment with anti-CD25 mAb resulted in the Cytotoxicity Assay
In vivo primed CD8 T cells were cultured with Na251CrO4 (NEN Lifedepletion of 	98% of spleen CD4CD25 T cells in rDC-treated
recipients 16 days after transplantation. In another experiment, re- Science Products, Boston, MA)-labeled P815 cells (104 ), EL4 cells
(104, RIKEN Cell Bank), or Con A blasts (104 ) (Sato et al., 1999) forcipients (H-2d) of BMS (H-2b) were injected 2 days after transplanta-
tion with unprimed CD4CD25 T cells (106/mouse, H-2b), 4 hr at various effector cell to target cell ratios (E/T ratios). The
radioactivity of the supernatants was measured, and the percentCD4CD25 T cells (106/mouse, H-2b) obtained from mDC-treated
recipients 5 days after transplantation, or CD4CD25 T cells (106/ specific lysis was calculated (Sato et al., 1999).
mouse, H-2b) obtained from rDC-treated recipients 60 days after
transplantation. Recipients were monitored once every day from the
Enzyme-Linked Immunosorbent Assayday of transplantation as described above.
Mice were anesthetized and exsanguinated; their blood was clotted
on ice for 10 min. Serum was then separated by centrifugation and
stored at –80C for further analysis and was measured in duplicateIn Vivo Priming of T Cell Subsets
wells. The murine IFN-, TNF-, and IL-12p40 were measured usingTransplantation with allogeneic BMS (3  107/mouse) was per-
ELISA kits purchased from BioSource (Camarillo, CA).formed in the following strain combinations: recipients (H-2d) versus
BMS (H-2b), recipients (H-2b) versus BMS (H-2d), and recipients (H-2q)
versus BMS (H-2d). Spleen mononuclear cells were 	95% donor-
Measurement of cAMP Concentrationmatched I-K cells 5 days after transplantation, and they were ob-
Unprimed or primed CD4 T cells (106 ) were isolated as describedtained by the depletion of recipient cells with recipient-matched
above, and the concentration of intracellular cAMP was determinedanti-I-K mAb plus goat anti-mouse IgG mAb-conjugated immuno-
by enzyme immunoassay (BIOMOL Research Laboratories, Plym-magnetic beads at 2  107/mouse, and donor-derived CD4 T
outh Meeting, PA).cells and CD8 T cells were then obtained at 4  106/mouse as
described above. Similarly, donor-derived CD4 T cells and CD8
T cells were collected from spleen mononuclear cells in mDC- or
Immunoblotting
rDC-treated recipients of allogeneic BMS (3 107/ mouse or2
Total cell lysates were collected from isolated CD4 T cells (4 
107/mouse) at 107/mouse or 3  106/mouse, respectively. Cells
106 ). Protein samples were fractionated by 12% SDS-PAGE, trans-
were then rested in medium containing murine IL-2 (10 U/ml) for 3
ferred onto PVDF membranes (Millipore, Bedford, MA), and probed
days and used for subsequent experiments.
with anti- p27kip1Ab (Transduction Laboratories, Lexington, KY) plus
horseradish peroxidase-conjugated secondary Abs (Santa Cruz Bio-
tech, Santa Cruz, CA). Blots were visualized by enhanced chemilumi-In Vivo Behavior of rDCs in Mice
nescence (New England Biolabs, Beverly, MA) (Sato et al., 1999).rDCs (H-2b) were labeled with CFSE (Molecular Probes, Eugene, OR)
and injected i.v. into the recipients (H-2d) of BMS (H-2b) at 1.5  106/
mouse. Spleen mononuclear cells were collected at various intervals Analysis of Tr Cell Function
and analyzed by flow cytometry. For preparation of in vivo infused Unprimed CD4CD25 T cells were isolated from spleen CD4 T
rDCs, host-mismatched rDCs were injected into recipients of third- cells in normal mice (H-2b) with anti-CD25 mAb plus sheep anti-rat
party allogeneic BMS because it is difficult to obtain the injected IgG mAb-conjugated immunomagnetic beads. I-KbCD4CD25 T
rDCs from syngeneic recipients with a high purity. In brief, rDCs cells were also selected from spleen I-KbCD4 T cells in mDC- or
(H-2d) were collected from spleen mononuclear cells in rDC (H-2d)- rDC-treated recipients of allogeneic BMS on the indicated days as
treated recipients (H-2b) of allogeneic BMS (H-2q) 5 days after trans- described above, and they were typically 	90% pure as indicated
plantation using anti-I-Kd mAb plus goat anti-mouse IgG mAb-conju- by FACS analysis. CD4 T cells (105, H-2b) were cultured with or
gated immunomagnetic beads, and assayed for phenotype and allo- without mDCs (104, H-2d or H-2q) in the presence or absence of
geneic T cell ability. different numbers of unprimed CD4CD25 T cells or
I-KbCD4CD25 T cells (2  104– 105 ) in 96-well plates. For
Transwell experiments, I-KbCD4CD25 T cells (106 ) plus mDCs
Flow Cytometry
(105, H-2d) were either added directly to the coculture of CD4 T
Cells were stained with fluorescein-conjugated mAbs to CD3, CD4,
cells (106, H-2b) with mDCs (105, H-2d) in 24-well plates (Coster) or
CD8, CD11c, CD25, CD40, CD80, CD86, CD152, CD154, I-K, I-A/
were placed separately in 24-well Transwell cell culture chambers
I-E, and isotype-matched control mAb (all from BD PharMingen).
(Millicell, Milipore, Bedford, MA) in the same well for 4 days. Follow-
Alternatively, intracellular analysis of the expression of cytokines
ing depletion of mDCs, total T cells (105 /well) were transferred to
was performed according to the manufacturer’s instructions with
96-well plates. The proliferation of activated T cells was evaluated
some modification. In brief, CD4 T cells were stimulated with
on day 5 based on [3H]thymidine incorporation.
platebound anti-CD3 mAb (10 
g/ml, BD PharMingen) plus soluble
anti-CD28 mAb (10 
g/ml, BD PharMingen) for 6 hr. 2 
M monensin
(Sigma) was added for the last 5 hr of culture. Cells were collected, Statistical Analysis
washed, fixed, saponin-permeabilized (fix/perm solution, BD Phar- Data are expressed as mean values  standard deviation (SD). All
Mingen), and stained with fluorescein-conjugated mAbs to IL-2, IL-4, analyses for statistically significant differences were performed with
IL-10, and IFN- (all from BD PharMingen). Analysis of fluorescence Student’s paired t test or Mann-Whitney’s U test. P values 0.01
staining was performed with a FACScan flow cytometer and CELL- were considered significant.
Quest Software, and data are expressed as percent mean positive
cells or mean fluorescence intensity (MFI).
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